Day: March 23, 2020

SCOTTSDALE, Ariz., March 23, 2020 (GLOBE NEWSWIRE) — TPI Composites, Inc. (Nasdaq: TPIC), the only independent manufacturer of composite wind blades with a global footprint, today published its first sustainability report highlighting its Environmental, Social and Governance (ESG) initiatives. TPI is committed to advance the decarbonization of the electric sector and electrification of the vehicle fleet.The report highlights how TPI has incorporated sustainability and ESG into our day-to-day operations, TPI’s substantial improvement in safety over the last four years, and the significant potential contribution to global emissions reduction resulting from wind blades sold in 2019.“We are proud to present our first sustainability report and ESG initiatives to our stakeholders,” said Steve Lockard, CEO of TPI Composites. “This is one...

SAMPO PLC                        MANAGERS’ TRANSACTIONS                  23 March 2020 at 2:00 pmSampo plc: Managers’ Transactions (Tetrao SA)Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the Market Abuse Regulation.____________________________________________Person subject to the notification requirementName: Tetrao SAPosition: Closely associated person(X) Legal person(1): Person Discharging Managerial Responsibilities In IssuerName: Björn WahlroosPosition: Member of the BoardIssuer: Sampo plcLEI: 743700UF3RL386WIDA22Notification type: INITIAL NOTIFICATIONReference number: 743700UF3RL386WIDA22_20200323125129_6____________________________________________Transaction date: 2020-03-23Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTISIN: XS1995716211Nature...

SAMPO OYJ                                              JOHDON LIIKETOIMET       23.3.2020 klo 14.00Sampo Oyj: Johdon liiketoimet (Tetrao SA)Sampo Oyj (Y-tunnus 0142213-3) on vastaanottanut seuraavan markkinoiden väärinkäyttöasetuksen 19. artiklan mukaisen ilmoituksen.____________________________________________IlmoitusvelvollinenNimi: Tetrao SAAsema: Lähipiiriin kuuluva henkilö(X) Oikeushenkilö(1): Liikkeeseenlaskijassa johtotehtävissä toimiva henkilöNimi: Björn WahlroosAsema: Hallituksen jäsen/varajäsenLiikkeeseenlaskija: Sampo OyjLEI: 743700UF3RL386WIDA22Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 743700UF3RL386WIDA22_20200323125129_6____________________________________________Liiketoimen päivämäärä: 2020-03-23Kauppapaikka ei sovelluInstrumenttityyppi: RAHOITUSINSTRUMENTTI, JOKA LIITTYY OSAKKEESEEN TAI VIERAAN PÄÄOMAN EHTOISEEN...

Phase III VIALE-A study showed Venclexta/Venclyxto plus azacitidine helped people with the most common type of aggressive leukaemia in adults live longer compared to azacitidine aloneData will be shared with global health authorities and presented at an upcoming medical meetingBasel, 23 March 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine...

Malta, 23 March 2020Kambi Group plc: Exercise of options In the exercise window ended on 19 March 2020, under the rules of the Kambi Group plc Share Option Plan 2013 introduced in December 2013, 307,500 options were exercised.Following this exercise, the total number of shares in Kambi Group plc will be 30,829,697 shares after Malta Stock Exchange’s issuance of the new shares, with a par value of EUR 0.003 per share. For more information, please contact:Mia Nordlander, Head of Investor Relationsmia.nordlander@kambi.com+44 (0)785 091 0933www.kambi.com About KambiKambi is a provider of premium sports betting services to licensed B2C gaming operators. Kambi Group plc is listed on First North Growth Market at Nasdaq Stockholm. Our services encompass a broad offering from front-end user interface through to odds compiling, customer intelligence...

GREENSBORO, N.C., March 23, 2020 (GLOBE NEWSWIRE) — HF Foods Group Inc. (NASDAQ: HFFG), a leading food distributor to Asian restaurants across the Southeast, Pacific and Mountain West regions of the United States (the “Company”), has appointed Russell Libby, a food distribution industry veteran and service-oriented c-suite executive, to the Company’s board of directors effective July 1, 2020.Libby will replace Zhehui Ni, who resigned effective June 30, 2020, due to personal and professional obligations. As a result of the change, the Company’s board of directors will remain composed of five directors, including three independent directors and two inside directors.Russell Libby has nearly 30 years of experience in mergers and acquisitions, strategy, business development, international business, corporate governance, and corporate...

Der indkaldes til ordinær generalforsamling i Investeringsforeningen Sparinvest med tilhørende afdelinger, torsdag den 16. april 2020, kl. 17.00.Den ordinære generalforsamling afholdes som fuldstændig elektronisk generalforsamling uden adgang til fysisk fremmøde. Deltagelse på den ordinære generalforsamling sker via InvestorPortalen, som der er ad­gang til på foreningens hjemmeside sparinvest.dk.På InvestorPortalen er det muligt at tilmelde sig den ordinære generalforsamling samt at afgive fuldmagt til bestyrelsen eller tredjemand.Der gøres opmærksom på, at der vil være en spørgerunde forud for den ordinære generalforsamling, hvor det vil være muligt at stille spørgsmål til årsrapporten 2019 og udviklingen i foreningen. Eventuelle spørgsmål kan stilles via InvestorPortalen, hvor også svar fra bestyrelsen og direktionen vil blive offentliggjort.Spørgerunden...

GAITHERSBURG, Md., March 23, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN) announced today that its Acuitas Lighthouse® was used in a study conducted by the Mayo Clinic to predict phenotypic resistance and antimicrobial susceptibility among clinical isolates from the Antimicrobial Resistance Leadership Group (ARLG). The findings were published in Diagnostic Microbiology & Infectious Disease, a peer-reviewed scientific journal providing the latest developments in clinical microbiology and the diagnosis and treatment of infectious diseases.The manuscript titled ‘Core genome MLST and resistome analysis of Klebsiella pneumoniae using a clinically-amenable workflow,’ was authored by a team of researchers at Mayo Clinic and others in the ARLG.The manuscript showcases the use of core genome multi locus sequence typing (cgMLST)...

WASHINGTON, March 23, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the expansion of its Health Solutions practice with the recent addition of five U.S.-based professionals, including Senior Managing Director Bruce Hallowell and Managing Directors Kathleen Fitzgerald, Lucy Lee, Michael Moran and Pam Robertson.“The healthcare industry is increasingly challenged by operational and regulatory demands, higher risks of compliance and pressures for fundamental realignment and improved value,” said Charles Overstreet, Global Leader of the Health Solutions practice at FTI Consulting. “The appointments of Bruce, Kathy, Lucy, Michael and Pam represent our commitment to enhancing the breadth and depth of our Health Solutions capabilities, so we’re better equipped to help clients navigate their ever-evolving challenges....

ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET will be presented at the American College of Cardiology’s 69th Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) on March 28th – 30th 2020.Esperion completed its global, pivotal, Phase 3 LDL-C lowering development program and announced positive cumulative results in October 2018. The program evaluated the safety, tolerability and LDL-C lowering efficacy of NEXLETOL and NEXLIZET in patients with hypercholesterolemia who either have atherosclerotic cardiovascular disease (ASCVD) or are at high risk of ASCVD, and who continue to have elevated levels of LDL-C despite the use of maximally-tolerated...